MNG679
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PEROXISOME+0.236
- PROTEIN_SECRETION+0.236
- UNFOLDED_PROTEIN_RESPONSE+0.232
- BILE_ACID_METABOLISM+0.208
- MITOTIC_SPINDLE+0.170
- MYC_TARGETS_V2+0.133
- ADIPOGENESIS+0.084
- DNA_REPAIR+0.082
- XENOBIOTIC_METABOLISM+0.082
- E2F_TARGETS+0.077
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.563
- ANGIOGENESIS-0.488
- INFLAMMATORY_RESPONSE-0.421
- IL6_JAK_STAT3_SIGNALING-0.401
- KRAS_SIGNALING_UP-0.338
- ALLOGRAFT_REJECTION-0.331
- APOPTOSIS-0.315
- NOTCH_SIGNALING-0.304
- IL2_STAT5_SIGNALING-0.284
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.259
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-G2-A3VY-01A-11R-A22U-07 | — | — | 0.832 |
| 2 | SRR655864 | GTEX | — | 0.814 |
| 3 | SRR661290 | GTEX | — | 0.801 |
| 4 | SRR662871 | GTEX | — | 0.799 |
| 5 | MDT-AP-0135 | Med | Medulloblastoma | 0.798 |
| 6 | TCGA-GV-A3JW-01A-11R-A20F-07 | — | — | 0.790 |
| 7 | TCGA-E9-A1R7-01A-11R-A14M-07 | — | B | 0.790 |
| 8 | SRR1080927 | GTEX | — | 0.785 |
| 9 | SRR657325 | GTEX | — | 0.784 |
| 10 | SRR664819 | GTEX | — | 0.784 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PEROXISOME | 0.236 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.236 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.232 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.208 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.170 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.133 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.084 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.082 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.082 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.077 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.072 | Inavolisib | — uncovered |
| MYOGENESIS | 0.062 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.050 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.037 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.028 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.025 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.013 | Temsirolimus | — uncovered |